Meeting patient expectations in migraine treatment: what are the key endpoints?

被引:11
作者
Antonaci, Fabio [1 ,2 ]
Sances, Grazia [2 ]
Guaschino, Elena [2 ]
De Cillis, Ilaria [2 ]
Bono, Giorgio [1 ]
Nappi, Giuseppe [2 ]
机构
[1] UCADH, Sect Varese, Pavia, Italy
[2] IRCCS C Mondino Fdn, Headache Ctr, Pavia, Italy
关键词
Migraine treatment; Outcome; Quality of life;
D O I
10.1007/s10194-008-0052-8
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Clinical outcomes of migraine treatment are generally based on two major endpoints: acute pain resolution and effects on quality of life (QOL). Resolution of acute pain can be evaluated in a number of ways, each increasingly challenging to achieve; pain relief, pain freedom at 2 h, sustained pain-freedom, and SPF plus no adverse events (SNAE, the most challenging). QOL questionnaires help assess the burden of migraine and identify optimal treatments. Pain resolution and improved QOL form the basis of the ultimate target-meeting patient expectations, to achieve patient satisfaction. To achieve this, it is crucial to choose appropriate endpoints that reflect realistic treatment goals for individual patients. Moreover, SNAE can help discriminate between triptans, with almotriptan having the highest SNAE score. Kaplan-Meier plots are also relevant when evaluating migraine treatments. The use of symptomatic medication may lead to the paradoxical development of medication-overuse headache. In general practice, patients should use simple tools for pain measurement (e. g. headache diary) and a QOL questionnaire. A composite endpoint of pain resolution and QOL restoration would constitute a step forward in migraine management.
引用
收藏
页码:207 / 213
页数:7
相关论文
共 25 条
[1]   Lessons from placebo effects in migraine treatment [J].
Antonaci F. ;
Chimento P. ;
Diener H.-C. ;
Sances G. ;
Bono G. .
The Journal of Headache and Pain, 2007, 8 (1) :63-66
[2]   Health-related quality of life among Canadians with migraine [J].
Brna P. ;
Gordon K. ;
Dooley J. .
The Journal of Headache and Pain, 2007, 8 (1) :43-48
[3]   Identification of negative predictors of pain-free response to triptans: Analysis of the eletriptan database [J].
Diener, H-C ;
Dodick, D. W. ;
Goadsby, P. J. ;
Lipton, R. B. ;
Almas, M. ;
Parsons, B. .
CEPHALALGIA, 2008, 28 (01) :35-40
[4]   Use of the sustained pain-free plus no adverse events endpoint in clinical trials of triptans in acute migraine [J].
Dodick, David W. ;
Sandrini, Giorgio ;
Williams, Paul .
CNS DRUGS, 2007, 21 (01) :73-82
[5]   Medication overuse headache in patients with primary headache disorders - Epidemiology, management and pathogenesis [J].
Dowson, AJ ;
Dodick, DW ;
Limmroth, V .
CNS DRUGS, 2005, 19 (06) :483-497
[6]   Defining response in migraine: Which endpoints are important? [J].
Edmeads, J .
EUROPEAN NEUROLOGY, 2005, 53 :22-28
[7]   Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment:: a meta-analysis of 53 trials [J].
Ferrari, MD ;
Roon, KI ;
Lipton, RB ;
Goadsby, PJ .
LANCET, 2001, 358 (9294) :1668-1675
[8]   Treating early versus treating mild: Timing of migraine prescription medications among patients with diagnosed migraine [J].
Foley, KA ;
Cady, R ;
Martin, V ;
Adelman, J ;
Diamond, M ;
Bell, CF ;
Dayno, JM ;
Hu, XH .
HEADACHE, 2005, 45 (05) :538-545
[9]  
Gladstone J, 2003, SEMIN NEUROL, V23, P265
[10]  
GOADSBY PJ, 2008, CEPHALALGIA IN PRESS